RT @uptoTate: MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. h…
Tweet Content
MAXIMISE results in axial manifestations of PsA. SEC met primary phase 3b ASAS 20 endpoint after inadequate NSAID response. https://t.co/e1j03KOo1K #ACR19 @RheumNow abs#2880 https://t.co/UtSDJGAW2G
Links
Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis …
http://ow.ly/1jPl50x3Cuf
Show on Archive Page
On
Display in Search Results
On